Biodexa Pharmaceuticals American Depositary Shs (BDRX) vs Scinai Immunotherapeutics (SCNI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Scinai Immunotherapeutics is the larger company by market cap ($1.6 million vs $1.0 million), about 1.6 times the size. On valuation, Biodexa Pharmaceuticals American Depositary Shs trades at a lower trailing P/E (0.0x vs 0.0x for Scinai Immunotherapeutics).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDRX | SCNI |
|---|---|---|
| Share price | $0.4602 | $1.18 |
| Market cap | $1.01M | $1.60M |
| 1-day change | -12.13% | -2.48% |
| P/E ratio (TTM) | 0.01 | 0.04 |
| EPS (TTM) | $56.08 | $28.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $44.80 | $15.65 |
| 52-week low | $0.45 | $1.06 |
| Distance from 52-week high | -98.97% | -92.46% |
| Analyst consensus | none | — |
| Avg. price target upside | +1836.11% | — |
| Average volume | 3.78M | 1.12M |
| Shares outstanding | 2.20M | 1.35M |
| Employees | 11 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Scinai Immunotherapeutics trades at a higher earnings multiple (0.0x vs 0.0x trailing P/E).
About Biodexa Pharmaceuticals American Depositary Shs
BDRX stock →Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees
About Scinai Immunotherapeutics
SCNI stock →Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
BDRX vs SCNI FAQ
Which is bigger, Biodexa Pharmaceuticals American Depositary Shs or Scinai Immunotherapeutics?
Scinai Immunotherapeutics (SCNI) is larger, with a market capitalization of $1.60M compared with $1.01M for Biodexa Pharmaceuticals American Depositary Shs (BDRX).
Which has the lower P/E ratio, BDRX or SCNI?
BDRX has the lower trailing P/E at 0.0, versus 0.0 for SCNI. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Biodexa Pharmaceuticals American Depositary Shs and Scinai Immunotherapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Biodexa Pharmaceuticals American Depositary Shs and Biotechnology: Biological Products (No Diagnostic Substances) for Scinai Immunotherapeutics.